[HTML][HTML] Perampanel monotherapy for the treatment of epilepsy: clinical trial and real-world evidence
T Yamamoto, A Gil-Nagel, JW Wheless, JH Kim… - Epilepsy & Behavior, 2022 - Elsevier
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor antagonist, is a once-daily oral anti-seizure medication (ASM) for focal-onset …
acid receptor antagonist, is a once-daily oral anti-seizure medication (ASM) for focal-onset …
The AMPA receptor biophysical gating properties and binding site: Focus on novel curcumin-based diazepines as non-competitive antagonists
Introduction Investigating the binding site of six novel curcumin-based diazepine
compounds as a non-competitive antagonist on ionotropic, AMPA-type glutamate receptors …
compounds as a non-competitive antagonist on ionotropic, AMPA-type glutamate receptors …
Real-world analysis of retention on cenobamate in patients with epilepsy in the United States
S Stern, M Weingarten, S Mandapati, L Ferrari… - Epilepsy Research, 2023 - Elsevier
Background This retrospective, observational study used US claims data to assess retention
rates on cenobamate compared with four branded antiseizure medications (ASMs) in …
rates on cenobamate compared with four branded antiseizure medications (ASMs) in …
Research Status, Synthesis and Clinical Application of Antiepileptic Drugs
SJ Wang, MY Zhao, PC Zhao, W Zhang… - Current Medicinal …, 2024 - benthamdirect.com
According to the 2017 ILAE's official definition, epilepsy is a slow brain disease state
characterized by recurrent episodes. Due to information released by ILAE in 2017, it can be …
characterized by recurrent episodes. Due to information released by ILAE in 2017, it can be …
Initiating antiepilepsy treatment: an update of expert consensus in Spain
V Villanueva, JC Sánchez-Álvarez, M Carreño… - Epilepsy & Behavior, 2021 - Elsevier
Following publication in 2014 of the International League Against Epilepsy (ILAE) official
report changing the definition of epilepsy, a number of questions remain unresolved in …
report changing the definition of epilepsy, a number of questions remain unresolved in …
Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
E Trinka, R Rocamora, J Chaves, J Moreira, F Ikedo… - …, 2020 - Wiley Online Library
Objective To assess the efficacy, safety, and tolerability of eslicarbazepine acetate (ESL)
monotherapy during long‐term treatment. Methods An open‐label extension (OLE) study …
monotherapy during long‐term treatment. Methods An open‐label extension (OLE) study …
Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies
S Fernández-Anaya, V Villanueva… - International Journal …, 2023 - Taylor & Francis
Aim of the study To assess the effectiveness, overall tolerability of eslicarbazepine acetate
(ESL) as an initial or early monotherapy treatment of adult patients with focal epilepsy under …
(ESL) as an initial or early monotherapy treatment of adult patients with focal epilepsy under …
Eslicarbazepine Acetate: A Review in Focal-Onset Seizures
YA Heo - CNS drugs, 2020 - Springer
Eslicarbazepine acetate (Zebinix®), a voltage-gated sodium channel blocker, is a once-
daily, orally administered anti-seizure medication available in the EU for use as …
daily, orally administered anti-seizure medication available in the EU for use as …
Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure
Eslicarbazepine‐induced severe hyponatremia resulted in generalized tonic‐clonic seizure -
Habib - 2021 - Clinical Case Reports - Wiley Online Library Skip to Article Content Skip to Article …
Habib - 2021 - Clinical Case Reports - Wiley Online Library Skip to Article Content Skip to Article …